Background Recent studies have shown that immune checkpoint inhibitors (ICIs) targeting
programmed cell death-ligand 1 (PD-L1) have potential benefits in patients with non-small …

Objective Programmed cell death 1 (PD-1) and one of its ligands, PD-L1, are key immune
checkpoint proteins. Evidences showed PD-L1 is an emerging biomarker for immunotherapy …

Abstract Programmed cell death-1 (PD-1)-targeted immunotherapy has become a promising
treatment paradigm for patients with advanced non-small cell lung cancer (NSCLC). Clinical …

Background: Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-
L1) are important targets of immunotherapy and its expression has been closely correlated …

Introduction: Programmed death-ligand 1 (PD-L1) is regarded as a marker of immune
tolerance and its expression is considered to be useful for immunotherapy by immune …

Background Programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-
L1) checkpoint inhibitors have demonstrated antitumor activity, and immunohistochemical …

Background Immunotherapies using anti-programmed cell death ligand-1 (PD-L1) agents
have recently shown remarkable outcomes in patients with non-small cell lung cancer …

Introduction PD-L1 expression is a predictive biomarker for response to anti-programmed
cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors …

Background Immune checkpoint inhibitors that target the programmed cell death protein
ligand 1 (PD-L1) pathway have shown benefit for the treatment of metastatic non-small cell …

Background Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1)
have been identified as novel targets for immunotherapy, with PD-L1 as a potential …